Cloud Hanging Over General Electric As the Company’s Shares Witness The Heaviest Fall In A Decade

Cloud Hanging Over General Electric As the Company’s Shares Witness The Heaviest Fall In A Decade

General Electric (NYSE: GE) is a leading global high-tech industrial company with products and services ranging from power generation, aircraft engines, financing and industrial products & oil and gas production equipment.

General Electric’s shares have fallen down drastically in response to the recent news alleging that the company has come up with misleading and fraudulent financial statements, hiding its financial problems. In Thursday’s trading session, the stock went down by 11.3% and ended at a price of $8.01. Prior to this, the stock last saw a major decline in April 2008 when the shares fell by 12.79%. Due to Thursday’s trading session, the stock’s year-to-date returns went down to around 3%.

The company saw the threat falling upon it, when Harry Markopolos, a whistleblower on the Bernie Madoff’s Ponzi Scheme, released a 175 pages report that stated the company’s financial problems in detail and problems in accounting issues related to its oil and gas unit. The company also stressed the need for the company to raise its insurance reserves.

The report released states General Electric as a bigger fraud than Enron. As per the research done by the whistleblower, the discovered fraud has left General Electric on the verge of insolvency. On analysing the company’s position for a period of 7 months, the researcher and his team identified a fraud of $38 billion. This amount, they say, is just a minor part of the actual fraud stating that the company has a long history of accounting fraud, dating back yo 1995.

As per few media reports, the company may not survive this turmoil for long and possibly be required to file for bankruptcy.

Excerpts from Markopolos’ Report:

In the report prepared by the researcher, General Electric was accused of hiding potential losses worth US$38 billion. The report stated that the company’s debt and cash position was worse that what it appeared to be prima facie. Against the debt to equity ratio of 3:1, disclosed by the company in its financials, Markopolos’ report mentioned that the company is extremely debt-ridden with true debt to equity ratio of 17:1.

In addition, the report claimed the company to be insolvent, with a working capital deficit of US$20 billion in relation to its industrial units. The report also focused on the company’s long-term insurance unit, that required the company to increase its reserves by $15 billion last year. The researcher examined other companies in the same business and concluded that GE has been hiding huge losses which will amplify as the policyholders grow older.

The report also contained some issues regarding the company’s accounting on its oil and gas business, Baker Hughes. As stated in the report, GE’s case appears to be far more serious than Enron or WorldCom with an accounting fraud estimating to US$38 billion that accounts for almost 40% of its market capitalisation.

GE’s Defence:

As per few media reports, the company’s CEO declared the 175-pager report as pure market manipulation containing factual errors. GE stated that the report released by Markopolos is an attempt to generate profits from short selling of the company’s stock to create unnecessary volatility. The company stated that it has maintained its financial reporting to the highest level of integrity and has disclosed its financial obligations in detail. In response to allegations in the report regarding increase in reserves, the company stated that it currently holds sufficient amount of reserves to support its portfolio characteristics.

Addressing the allegations regarding its liquidity, the company claims to have a strong liquidity position, having ended the second quarter with $16.9 billion of Industrial cash, access to credit facilities worth $35 billion and $12.5 billion liquidity at GE Capital. As a response to the stock movement, the company’s CEO Lawrence Culp purchased 252,000 shares at $7.93 each, making a total investment of $2 million.

Financial Highlights:

In the financial results for second quarter of 2019, the company reported a growth of 4% in organic orders as compared to prior corresponding period. Organic revenue growth for the industrial segment was reported at 7% and the backlog went up by 11% amounting to $396 billion over prior year. Growth in the backlog was partially supported by the company’s record wins at the Paris Air Show. The period saw a contraction of 300 basis points in the industrial organic profit margins owing to declines in GE Renewable Energy, GE Power and GE Aviation. Adjusted earnings per share for the period were recorded at $0.17, that included a benefit amounting to $0.06 from resolution of a tax audit matter.

The company is continuously focused on improving its financial position, as suggested by the recent changes in stake, fund settlement, sale of business etc; some of the which are explained below:

  • In the second quarter, the company reduced its stake in Wabtec to 12% through sale of a part of its holding, generating cash proceeds of $1.8 billion.
  • The company is on track to complete the sale of its BioPharma business, which is a part of the Life Science division of GE Healthcare. The sale which is expected to take place in the fourth quarter of 2019, will establish the BioPharma business as a separate entity, giving it additional resources to grow. For GE, the disposal of the BioPharma business is expected to result in a strong balance sheet position with cash proceeds of more than $20 billion.
  • In 2019, the company has been under process of reducing the assets of GE Capital, with approximately $2 billion assets cut down year-to-date. The company is targeting a reduction amounting to $10 billion in 2019 and has also moved approximately $4 billion of Aircraft lending receivables as assets held for sale.

Full-Year Outlook:

Based on the financial results of the second quarter, the company provided adjustments to its full-year outlook increasing the industrial free cash flows to a range of $ -1 billion to $1 billion, against the previous range of $ -2 billion to zero. Organic revenue growth for the year is now expected to be in the mid-single-digit range, against the previous growth guidance of low to mid-single digit. Adjusted EPS for the year is expected to be in the range of $0.55 to $0.65. Previously, the expected adjusted EPS was in the range of $0.50 to $0.60. Margin outlook for the year remained unchanged at flat to +100 bps. Restructuring expense which was earlier expected to be in the range of $2.4 billion to $2.7 billion, is now expected to be in the range of $1.7 billion to $2.0 billion.

Factors Driving the Revised Guidance:

The management stated that the company delivered upon its strategic priorities in 2Q’19 and will continue to work on improving its business for the benefit of its customers. The revised guidance for full year financial results came in as a result of power execution & the business’ return to profitability which depicts early signs of progress in performance. During the quarter, the company continued to strengthen the Aviation and Healthcare businesses. As a result of execution of projects at a lower than expected cost, the company lowered the guidance for restructuring expenses.

Backing its stand regarding the financial position, the company stated that it has reported better second quarter earnings than its expectations, along with a favorable full year outlook. Hence, the company declares the allegations made in Markopolos’ report to be false and misleading.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report